Clinical trials: Cannabis Use Disorder, Severe, open to volunteers
Cannabis Use Disorder, Severe
Cannabis and Processing Emotions Study
The goal of this study is to test a causal neural mechanism of cannabis use-related problem recognition in individuals with severe cannabis use disorder using a non-invasive form of neuromodulation called transcranial magnetic…
- Trial name
- CAPE (NCT06907979)
- Testing
- TMS - Active iTBS, TMS - Active cTBS
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Auburn University
Cannabis Use, Major Depressive Disorder
Extended Effects of Cannabis Abstinence on Clinical Symptoms and Cognition in Depression
The prevalence of major depressive disorder (MDD) is ~5.0%, and rates of co-occurring SUDs in these patients approach 40-50%. Specifically, rates of co-morbid cannabis use disorder (CUD) in patients with MDD are elevated 2-3 fold…
- Conditions
- Cannabis Use, Major Depressive Disorder, Cognitive Impairment
- Trial name
- NCT04935619
- Testing
- Contingency Reinforcement, Non-Contingency Reinforcement
- Where
- Canada
- Volunteers
- 52 people
- Sponsor
- Centre for Addiction and Mental Health
Mental Illness, Schizophrenia
Genetic Counselling in the Prevention of Mental Health Consequences of Cannabis Use
Severe mental illness (SMI) refers to the most burdensome psychiatric conditions. The need to pre-empt the onset of SMI is pressing because once SMI develops, quality of life is poor and available treatments have limited…
- Conditions
- Mental Illness, Schizophrenia, Bipolar Disorder, Major Depressive Disorder
- Trial name
- IMAGINE (NCT03601026)
- Testing
- Genetic counselling
- Where
- Canada
- Volunteers
- 120 people
- Sponsor
- Nova Scotia Health Authority
Depression - Major Depressive Disorder, Cannabis Use Disorder
Preliminary Efficacy Trial of a Digital Intervention for Depression and Cannabis Use
The purpose of this study is to examine the feasibility, acceptability, and preliminary efficacy of a digital intervention for co-occurring cannabis use and depression.
- Conditions
- Depression - Major Depressive Disorder, Cannabis Use Disorder, Mental Disorder
- Trial name
- NCT06878859
- Testing
- Amplification of Positivity - Cannabis Use (AMP-C)
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- Massachusetts General Hospital
Cannabis Use Disorder, Moderate, Cannabis Use Disorder, Severe
Tirzepatide in the Treatment of Cannabis Use Disorder
Cannabis is the most commonly used psychoactive substance in Canada. A sub-group of cannabis users develop Cannabis Use Disorder (CUD).
- Trial name
- NCT07671248
- Testing
- Tirzepatide
- Where
- Canada
- Volunteers
- 15 people
- Sponsor
- McMaster University
Cannabis Use Disorder, Major Depressive Disorder (MDD)
Pregnenolone for Cannabis Use Disorder and Depression
This is UG3 phase of a multi-site, milestone-driven UG3/UH3 research program evaluating pregnenolone for individuals with co-occurring cannabis use disorder (CUD) and major depressive disorder (MDD).
- Trial name
- PREG-CUD-MDD (NCT07685964)
- Testing
- Pregnenolone
- Where
- 2 sites in United States
- Volunteers
- 20 people
- Sponsor
- University of Texas Southwestern Medical Center